Furthermore, in ER+ve breast cancer models, dihydrotestosterone (DHT)-mediated activation of AR has been shown to inhibit ER-α signaling and cell cycle progression through a reduction in CCND1 transcription (66). Here, ESR1 is linked to breast cancer.